tumours

Showing 6 posts of 6 posts found.

First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617

December 15, 2023
Research and Development Cullinan Oncology, Oncology, clinical trial, tumours

Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …

volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

BioInvent and Transgene announce positive phase 1a solid tumour trial data

May 25, 2023
Research and Development BioInvent, Oncology, Transgene, clinical trials, oncology, tumours

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …

Breast cancer cells can be transformed into fat cells using combination therapy, study shows

January 16, 2019
Research and Development Cancer, EMT, breast cancer, cells, oncology, tumours

An innovative cancer treatment can turn malignant breast cancer cells into fat cells, thus preventing the formation of metastases (the …

T-cell

$350m collaboration deal for BMS and Five Prime Therapeutics

October 15, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

Logos

AstraZeneca and Peregrine in immuno-oncology collaboration

August 24, 2015
Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

R&D

Sanofi, Evotec and Apeiron partner on immuno-oncology

August 10, 2015
Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours

Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …

Latest content